BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Peng Z, Chen S, Xiao H, Wang Y, Li J, Mei J, Chen Z, Zhou Q, Feng S, Chen M, Qian G, Peng S, Kuang M. Microvascular Invasion as a Predictor of Response to Treatment with Sorafenib and Transarterial Chemoembolization for Recurrent Intermediate-Stage Hepatocellular Carcinoma.Radiology. 2019;292:237-247. [PMID: 31135299 DOI: 10.1148/radiol.2019181818] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang LZ, Hu XX, Shen XC, Wang TC, Zhou S. Intraarterial Lidocaine Administration for Pain Control by Water-in-Oil Technique in Transarterial Chemoembolization: in vivo and Randomized Clinical Trial. J Hepatocell Carcinoma 2021;8:1221-32. [PMID: 34676180 DOI: 10.2147/JHC.S331779] [Reference Citation Analysis]
2 Liu KC, Hao YH, Lv WF, Jia WD, Ji CS, Zhou CZ, Cheng DL, Xu SB, Gao ZG, Su MX, Shi CS. Transarterial Chemoembolization Combined with Sorafenib in Patients with BCLC Stage C Hepatocellular Carcinoma. Drug Des Devel Ther 2020;14:3461-8. [PMID: 32904650 DOI: 10.2147/DDDT.S248850] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
3 Cheng Z, Wei-Qi J, Jin D. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochim Biophys Acta Rev Cancer 2020;1874:188382. [PMID: 32522600 DOI: 10.1016/j.bbcan.2020.188382] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Wang TC, An TZ, Li JX, Pang PF. Systemic Inflammation Response Index is a Prognostic Risk Factor in Patients with Hepatocellular Carcinoma Undergoing TACE. Risk Manag Healthc Policy 2021;14:2589-600. [PMID: 34188570 DOI: 10.2147/RMHP.S316740] [Reference Citation Analysis]
5 Lin PT, Teng W, Jeng WJ, Hsieh YC, Hung CF, Huang CH, Lui KW, Chen YC, Lin CC, Lin CY, Sheen IS, Lin SM. Add-on sorafenib is beneficial for hepatocellular carcinoma patients with transarterial chemoembolization refractoriness: a real-world experience. Eur J Gastroenterol Hepatol 2020;32:1192-9. [PMID: 31851084 DOI: 10.1097/MEG.0000000000001637] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Ren Q, Zhu P, Li C, Yan M, Liu S, Zheng C, Xia X. Pretreatment Computed Tomography-Based Machine Learning Models to Predict Outcomes in Hepatocellular Carcinoma Patients who Received Combined Treatment of Trans-Arterial Chemoembolization and Tyrosine Kinase Inhibitor. Front Bioeng Biotechnol 2022;10:872044. [DOI: 10.3389/fbioe.2022.872044] [Reference Citation Analysis]
7 Chen Q, Xiao H, Gu Y, Weng Z, Wei L, Li B, Liao B, Li J, Lin J, Hei M, Peng S, Wang W, Kuang M, Chen S. Deep learning for evaluation of microvascular invasion in hepatocellular carcinoma from tumor areas of histology images. Hepatol Int. [DOI: 10.1007/s12072-022-10323-w] [Reference Citation Analysis]
8 Luo M, Chen SL, Chen J, Yan H, Qiu Z, Chen G, Lu L, Zhang F. Resection vs. ablation for lesions characterized as resectable-ablative within the colorectal liver oligometastases criteria: a propensity score matching from retrospective study. PeerJ 2020;8:e8398. [PMID: 32025372 DOI: 10.7717/peerj.8398] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Li X, Wang Y, Ye X, Liang P. Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Front Mol Biosci 2021;8:635243. [PMID: 33928118 DOI: 10.3389/fmolb.2021.635243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wang C, Liao Y, Qiu J, Yuan Y, Zhang Y, Li K, Zou R, Wang Y, Zuo D, He W, Zheng Y, Li B, Yuan Y. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study. J Cancer Res Clin Oncol 2020;146:2669-80. [PMID: 32449005 DOI: 10.1007/s00432-020-03254-2] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Cao J, Dong Y, Fan P, Mao F, Chen K, Chen R, Huang B, Cheng Y, Wang WP. Early evaluation of treatment response to transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The role of dynamic three-dimensional contrast-enhanced ultrasound. Clin Hemorheol Microcirc 2021. [PMID: 33682701 DOI: 10.3233/CH-201086] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Feng B, Ma XH, Wang S, Cai W, Liu XB, Zhao XM. Application of artificial intelligence in preoperative imaging of hepatocellular carcinoma: Current status and future perspectives. World J Gastroenterol 2021; 27(32): 5341-5350 [PMID: 34539136 DOI: 10.3748/wjg.v27.i32.5341] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Wang G, Zou H, Feng Y, Zhao W, Li K, Liu K, Zhang B, Zhu C. A Novel Four-Gene Signature as a Potential Prognostic Biomarker for Hepatocellular Carcinoma. J Oncol 2021;2021:1452801. [PMID: 34950206 DOI: 10.1155/2021/1452801] [Reference Citation Analysis]
14 Fu S, Pan M, Zhang J, Zhang H, Tang Z, Li Y, Mu W, Huang J, Dong D, Duan C, Li X, Wang S, Chen X, He X, Yan J, Lu L, Tian J. Deep Learning-Based Prediction of Future Extrahepatic Metastasis and Macrovascular Invasion in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1065-76. [PMID: 34513748 DOI: 10.2147/JHC.S319639] [Reference Citation Analysis]
15 Wang TC, Zhang ZS, Xiao YD. Determination of Risk Factors for Pain After Transarterial Chemoembolization with Drug-Eluting Beads for Hepatocellular Carcinoma. J Pain Res 2020;13:649-56. [PMID: 32273750 DOI: 10.2147/JPR.S246197] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wang K, Xiang YJ, Yu HM, Cheng YQ, Qin YY, Wang WJ, Zhang XP, Zheng YT, Shan YF, Cong WM, Dong H, Lau WY, Cheng SQ. A novel classification in predicting prognosis and guiding postoperative management after R0 liver resection for patients with hepatocellular carcinoma and microvascular invasion. Eur J Surg Oncol 2021:S0748-7983(21)01438-4. [PMID: 34996665 DOI: 10.1016/j.ejso.2021.12.466] [Reference Citation Analysis]
17 Zhou Q, Wang X, Li R, Wang C, Wang J, Xie X, Li Y, Li S, Mao X, Liang P. Sorafenib as adjuvant therapy following radiofrequency ablation for recurrent hepatocellular carcinoma within Milan criteria: a multicenter analysis. J Gastroenterol 2022. [PMID: 35816221 DOI: 10.1007/s00535-022-01895-3] [Reference Citation Analysis]
18 Wang TC, An TZ, Li JX, Zhang ZS, Xiao YD. Development and Validation of a Predictive Model for Early Refractoriness of Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. Front Mol Biosci 2021;8:633590. [PMID: 33816555 DOI: 10.3389/fmolb.2021.633590] [Reference Citation Analysis]
19 Malloy PC. Combination Therapy in Intermediate-Stage Hepatocellular Carcinoma: Do We Need to Know about Microvascular Invasion? Radiology 2019;292:248-9. [PMID: 31136261 DOI: 10.1148/radiol.2019190921] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Zhang X, Wang F, Gu G, Wu Q. High HBV Load Weakens Predictive Effect of Serum miR-122 on Response to Sorafenib in Hepatocellular Carcinoma Patients. J Oncol 2021;2021:9938207. [PMID: 34194500 DOI: 10.1155/2021/9938207] [Reference Citation Analysis]
21 Arora S, Catania R, Borhani A, Horvat N, Fowler K, Harmath C. HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy. Abdom Radiol (NY) 2021;46:3686-97. [PMID: 34195886 DOI: 10.1007/s00261-021-03192-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Wang W, Guo Y, Zhong J, Wang Q, Wang X, Wei H, Li J, Xiu P. The clinical significance of microvascular invasion in the surgical planning and postoperative sequential treatment in hepatocellular carcinoma. Sci Rep 2021;11:2415. [PMID: 33510294 DOI: 10.1038/s41598-021-82058-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
23 Zheng Z, Guan R, Jianxi W, Zhao Z, Peng T, Liu C, Lin Y, Jian Z, Wu YS. Microvascular Invasion in Hepatocellular Carcinoma: A Review of Its Definition, Clinical Significance, and Comprehensive Management. Journal of Oncology 2022;2022:1-10. [DOI: 10.1155/2022/9567041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Gu W, Tong Z. Sorafenib in the treatment of patients with hepatocellular carcinoma (HCC) and microvascular infiltration: a systematic review and meta-analysis. J Int Med Res 2020;48:300060520946872. [PMID: 32815430 DOI: 10.1177/0300060520946872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
25 Zhang T, Huang W, Dong H, Chen Y. Trans-catheter arterial chemoembolization plus Sorafenib, an unsuccessful therapy in the treatment of hepatocellular carcinoma?: A systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e20962. [PMID: 32702836 DOI: 10.1097/MD.0000000000020962] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Qiu Z, Shen L, Jiang Y, Qiu J, Xu Z, Shi M, Yu Z, Ma Y, He W, Zheng Y, Li B, Wang G, Yuan Y. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study. Ann Transl Med 2021;9:283. [PMID: 33708910 DOI: 10.21037/atm-20-5360] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Zhang Y, Wei Q, Huang Y, Yao Z, Yan C, Zou X, Han J, Li Q, Mao R, Liao Y, Cao L, Lin M, Zhou X, Tang X, Hu Y, Li L, Wang Y, Yu J, Zhou J. Deep Learning of Liver Contrast-Enhanced Ultrasound to Predict Microvascular Invasion and Prognosis in Hepatocellular Carcinoma. Front Oncol 2022;12:878061. [DOI: 10.3389/fonc.2022.878061] [Reference Citation Analysis]